Comparative Pharmacology
Head-to-head clinical analysis: KANAMYCIN SULFATE versus NEOMYCIN SULFATE POLYMYXIN B SULFATE HYDROCORTISONE.
Head-to-head clinical analysis: KANAMYCIN SULFATE versus NEOMYCIN SULFATE POLYMYXIN B SULFATE HYDROCORTISONE.
KANAMYCIN SULFATE vs NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing mRNA misreading.
Neomycin sulfate is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis in susceptible bacteria. Polymyxin B sulfate is a polypeptide antibiotic that disrupts bacterial cell membrane integrity by interacting with phospholipids. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating immune cell activity.
15 mg/kg/day IM or IV divided every 8-12 hours; typical adult dose: 500 mg IM every 12 hours or 7.5 mg/kg every 12 hours. Maximum total daily dose: 1.5 g.
Otic: Instill 3-5 drops into the affected ear(s) 3-4 times daily; for acute otitis externa, a wick may be used initially.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 30-60 hours in severe renal impairment (CrCl <10 mL/min).
Neomycin: 2-3 hours (renal impairment: up to 12-24 hours). Polymyxin B: 4.5-6 hours (prolonged in renal failure). Hydrocortisone: 1.5-2 hours.
Renal excretion of unchanged drug accounts for 80-90% of elimination; minor biliary excretion (<1%) and fecal elimination (<1%).
Neomycin is excreted primarily unchanged in feces (97%) after oral administration; absorbed fraction is renally excreted (30-50%). Polymyxin B is renally excreted (60%) with some biliary excretion. Hydrocortisone is metabolized hepatically and excreted renally as conjugates.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic